“This designation recognizes Dr. Daniel Janoff as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
July 31, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Daniel Janoff, M.D., Northwest Urology, LLC in Portland, OR, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Janoff has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Daniel Janoff as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

ROSA® WET-S5 Aflatoxin Quantitative Test Brochure

The certification marks the third approval of this test kit, which shows that the market favors water-based testing and continued success of lateral flow technology to test for aflatoxin.

LAWRENCE, Mass. (PRWEB)
July 30, 2020

Charm Sciences, Inc. announces that the United States Department of Agriculture’s Federal Grain Inspection Service (USDA-FGIS) has renewed the usage of the ROSA® WET®-S5 Aflatoxin Quantitative Test. This lateral flow test was first approved in 2014, again in 2017, and is reapproved for the detection of aflatoxin in barley, brown rice, corn, DDG, DDGS, hominy, sorghum, soybeans, and wheat.

“Charm Sciences is pleased to announce the reapproval of the ROSA WET-S5 Aflatoxin Quantitative Test,” stated Mark Tess, Ph.D., Mycotoxin Product Manager at Charm. “The certification marks the third approval of this test kit, which shows that the market favors water-based testing and continued success of lateral flow technology to test for aflatoxin.”

USDA-FGIS also awarded Charm a five-year contract to use the AFQ-WETS5 test to monitor aflatoxin in grains. USDA-FGIS operates and oversees official grain inspection services throughout the United States and will use the AFQ-WETS5 test for official aflatoxin testing. USDA-FGIS used the AFQ-WETS5 test for aflatoxin over the last five years as well.

“Charm Sciences is excited to be awarded the aflatoxin contract for another five years to test grains in the FGIS’s testing program,” said Dr. Tess. “The AFQ-WETS5 test is FGIS approved for 9 commodities and the 5-minute incubation time allows for rapid measurement to meet the demands of the program.”

The AFQ-WETS5 test utilizes Charm’s patented Rapid One Step Assay (ROSA) technology to extract aflatoxin from the sample without organic solvents. Like all of Charm’s ROSA mycotoxin tests, the AFQ-WETS5 test can be read and recorded using the all-in-one Charm EZ®-M System. The Charm EZ-M System allows incubation and analysis with the same equipment and is robust enough that tests can be run at the point of receiving.

To learn more about Charm Sciences, visit http://www.charm.com

About Charm Sciences, Inc.

Established in 1978 in Greater Boston, Charm Sciences helps protect consumers, manufacturers, and global brands from a variety of issues through the development of food safety, water quality, and environmental diagnostic tests and equipment. Selling directly and through its network of distributors, Charm’s products serve the dairy, feed and grain, food and beverage, water, healthcare, environmental, and industrial markets in more than 100 countries around the globe. https://www.charm.com

© 2020 Charm Sciences, Inc. Charm, Charm EZ, ROSA, and WET are registered trademarks of Charm Sciences, Inc.

Share article on social media or email:

By collaborating with AWS, we are bringing our combined skill sets together to develop solutions our healthcare providers need in order to work more efficiently and improve patient outcomes.

TAMPA, Fla. (PRWEB)
July 30, 2020

Greenway Health, a leading health information technology and services provider, today announced a new agreement with Amazon Web Services (AWS), Inc. The agreement will promote collaboration in the healthcare industry with the primary goal of developing transformative healthcare products that will further meet the needs of ambulatory care practices in a post-COVID world.

“Accelerating innovation and addressing the complex challenges facing our healthcare system is best accomplished by working together with collaboration and focus,” said Richard Atkin, CEO at Greenway. “By collaborating with AWS, we are bringing our combined skill sets together to develop solutions our healthcare providers need in order to work more efficiently and improve patient outcomes.”

Greenway will develop a new cloud-based, data services platform, Greenway InsightsTM, on AWS that creates new data insights and healthcare interventions to advance the breadth of Greenway’s products and services. Greenway Insights will leverage AWS cloud services, giving Greenway engineering teams direct access to a robust set of data analytics and machine learning capabilities, such as Amazon SageMaker and Amazon Comprehend Medical, that will enable product innovation to occur at an accelerated pace.

Initially, Greenway will leverage the platform to deliver a regulatory analytics solution to help customers meet the evolving reporting requirements of quality payment programs and value-based care initiatives. The solution will enable practices to receive data insights in real time, increasing practice performance and positively impacting patient outcomes.

“Technology is key to improving patient care and health outcomes. This collaboration via our Digital Innovation Program to deliver the Greenway Insights data and analytics platform will bring needed solutions to the market quickly,” said Paul Zimmerman, Worldwide Head, Private Equity at AWS. “Our team is currently working with three Vista portfolio companies on innovative solutions, and we are particularly proud of our work with Greenway. The project is operating on a rapid implementation timeline, and we have already seen initial success and proof of concept. We are looking forward to a continued collaboration in developing solutions that streamline workflows and improve the way healthcare providers care for their patients.”

Customers can expect more news and updates on these solutions in the coming months. For more information about Greenway, its solutions, and commitment to innovation, visit http://www.greenwayhealth.com/solutions.

About Greenway Health

Improving healthcare through innovation is at the heart of Greenway Health’s work. We provide electronic health record (EHR), practice management and revenue cycle management solutions that help practices in multiple specialties grow profitably, remain compliant, work more efficiently and improve patient outcomes. Our team of clinical, financial and technology experts serve as trusted advisers, committed to our customers’ success. Greenway works with over 55,000 providers across multiple specialties, which translates into millions of lives touched daily by our solutions. For details on how we can work together to build a more efficient healthcare system, visit http://www.greenwayhealth.com, call 877-537-0063, or follow Greenway on Facebook, Twitter, and LinkedIn.

Share article on social media or email:

“Dr. David Moore has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
July 30, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that David Moore, M.D., Deaconess Urology in Newburgh, IN, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Moore has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. David Moore has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Boston Business Journal Largest Corporate Charitable Contributor in Massachusetts

Our associates and residents are the heart of Benchmark, so doing what we can to support them and the causes that have deep, meaningful impact in their lives is critically important to us. -Tom Grape, Benchmark founder and CEO.

WALTHAM, Mass. (PRWEB)
July 29, 2020

Benchmark, a leading provider of senior living services in the Northeast, today announced that it has been named an honoree of Boston Business Journal’s 2020 Corporate Citizenship Awards. It’s the second consecutive year that the company has been named to the publication’s list of Largest Corporate Charitable Contributors in Massachusetts. Benchmark is the only senior care provider to be recognized.

“Our associates and residents are the heart of Benchmark, so doing what we can to support them and the causes that have deep, meaningful impact in their lives is critically important to us,” said Tom Grape, Benchmark’s founder and CEO. “Our charitable endeavors are among the many ways we carry out our mission of building human connections.”

In 2019, Benchmark supported the Alzheimer’s Association of Massachusetts and New Hampshire and the American Heart Association, both based in Waltham, and FriendshipWorks in Boston, among other organizations.

In addition to its support of community organizations, each year Benchmark raises funds through leadership and associate donations, as well as fundraising events, to support Benchmark’s One Company Fund. The 501(c)(3) organization, created in 2007, provides grants to associates in times of need.

Grape said he is especially proud that the Fund’s resources were available this year to support Benchmark associates who – like many people in the region – faced challenges presented by COVID-19.

“Helping one another as much as we can during these challenging times should be top of mind for everyone,” he said.

Associates and residents at Benchmark’s 61 independent living, assisted living and memory care communities also volunteer and raise funds for a host of local charities.

Throughout its history, Benchmark has continually been recognized as a top workplace. The Great Place to Work Institute certified Benchmark for two straight years, and the company earned a place on FORTUNE’s 50 Best Workplaces in Aging Services list each of the two years that the magazine published the list. Benchmark is one of only four companies to be named to The Boston Globe’s Top Place to Work all 12 years that the honor has been given.

Other companies recognized by Boston Business Journal included Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Mass General Brigham, and Tufts.

“These companies give back at least $100,000 to the local community, and now we are in a time when giving back and helping one another is more important than ever,” said Boston Business Journal Market President and Publisher Carolyn Jones. “These philanthropic companies prioritize the welfare of our communities, and we are excited to be able to honor them.”

# # #

About Benchmark

Based in Waltham, Mass., Benchmark is a leading provider of senior housing in the Northeast. It has 61 communities across Massachusetts, Connecticut, New Hampshire, Rhode Island, New York, Vermont, and Maine. Benchmark employs nearly 6,000 associates within its communities and corporate office. Founded in 1997 by Tom Grape, Benchmark offers independent living, assisted living, memory care and continuing care retirement communities. Click here for more information.

Share article on social media or email:

Esports in Court, Crimes in VR, and the 51% Attack provides insights into major events and developments in perhaps the most dynamic and rapidly evolving industries of our time: video games and esports

David Hoppe gives a fantastic take on esports and the wider games industry. “This book is very timely and contains a ton of information and links further exploration

SAN FRANCISCO (PRWEB)
July 29, 2020

Gamma Law, the premier specialty law firm supporting clients in selected high-growth and emerging business sectors, is pleased to announce that less than three months after its release, Managing Partner David B. Hoppe’s new book ranks 58th (as of July 27) among Entertainment Law books offered on Amazon.com’s Kindle Store. Esports in Court, Crimes in VR, and the 51% Attack: Key Trends and Developments in Esports, VR and AR, Blockchain and Cryptocurrencies chronicles Hoppe’s experiences representing and advising clients involved in today’s cutting-edge industries – augmented reality, digital media, blockchain, cryptocurrencies, esports, and more.

“David Hoppe gives a fantastic take on esports and the wider games industry,” said Paul Thind, founder and chief executive officer of Triggerspot, Inc., a digital entertainment consultancy. “This book is very timely and contains a ton of information and links further exploration.”

Amazon reviewers also provided high marks for the book, consistently giving it 5-star ratings. One reviewer described it as “a fun read,” while another said they appreciate Hoppe’s “significant insight into some of the most critical and influential industries of our time.”

Presented as a combination of entertaining anecdotes, thought-provoking essays, and concise infographics, Hoppe’s book examines the business dynamics and legal and ethical considerations inherent in these industries, offering both a historical perspective and a vision founded on 25 years’ experience representing established companies and emerging forces in these industries.

“I am extremely gratified by the reception the book has received, both on Amazon and among the professionals we serve,” Hoppe said. “The technologies behind these industries advance daily, and so do the regulations and laws –- both domestic and international –- that govern them. I tried to capture this progression and energy to demonstrate the possibilities and challenges facing participants.”

About David B. Hoppe

Gamma Law’s Managing Partner David Hoppe combines the sophistication and global perspective of an international transactional attorney with the hands-on understanding of the day-to-day realities of startups, growing companies, and enterprises going global. He began his career at two high-profile international law firms, Jones Day and White & Case, based in Tokyo, New York, Los Angeles, Stockholm, and Helsinki. He also served as International Counsel for Excite.com, a NASDAQ-listed web portal, and North America General Counsel of Capcom, the Japanese video game publisher.

About Gamma Law

Gamma Law supports select clients in emerging media and technology business sectors, including esports, video games, AR/VR/MR, blockchain, cryptocurrencies, and digital media. Gamma Law’s team is composed of legal specialists with experience in large international law firms and as in-house counsel for technology and entertainment companies in the US and Japan.

Contact:

Scott Smith

marketing@gammalaw.com

Share article on social media or email:

“This offer adds unparalleled value to our program in Lake Nona and to our portfolio companies. Ambitious founders that want to deploy AI in their solutions but lack the technical background will now have machine learning capabilities at their fingertips.” Christoph Sonnen, leAD Co-Founder and CEO

ORLANDO, Fla. (PRWEB)
July 29, 2020

leAD Sports and Health Tech Partners have announced a partnership with Stradigi AI, a leading North American Artificial Intelligence software company, to provide startups in the leAD Lake Nona program access to cutting edge AI technology. Through this partnership, selected early-stage sports and health tech companies that are part of the program in Lake Nona, Orlando, FL will be able to use Kepler, Stradigi AI’s newly launched self-service version of its Machine Learning platform. Kepler enables users with no previous Machine Learning and Deep Learning experience to reap the benefits of business-driving AI in hundreds of real-world applications, saving research and development costs and empowering non-technical founders and business users.

“Artificial Intelligence is extremely relevant also in the world of sports & health tech. Having the right tech partner by our side can really make a huge difference for our startup founders,” said Christoph Sonnen, leAD Co-Founder and CEO, ADvantage Sports Tech Fund Partner. “We are proud to welcome Stradigi AI, an AI software powerhouse and leader in this market, as our official tech partner. This offer adds unparalleled value to the leAD Lake Nona program and to our portfolio companies. Ambitious founders that want to deploy AI in their solutions but lack the technical background will now have machine learning capabilities at their fingertips. leAD is centered around smart investment and business growth – we’re very excited to see founders truly accelerate their development with this outstanding platform created by Stradigi AI!”

The Kepler platform provides end-to-end automation of complex data science processes with its new Automated Data Science Workflows. The automation features allow businesses to get AI projects to market quickly and securely, solving the most pressing use cases in the market today, including customer segmentation, churn prediction, demand forecasting, predictive maintenance, fraud detection, workforce planning, pricing optimization, and more, across all business verticals. The Kepler platform was created to effectively bridge the AI talent gap and accelerate enterprise-wide adoption of AI. It integrates built-in orchestration and decision making for time-consuming, expensive, and arduous tasks that data scientists undertake throughout the process of building and deploying ML models.

“Startups gain a significant advantage by onboarding AI early.” said Basil Bouraropoulos, CEO and Co-Founder at Stradigi AI. “Our partnership with leAD means their portfolio of sports and health businesses will have access to AI and ML capabilities at the important early stages of their growth. Our Kepler platform offers startups a significant competitive edge, allowing them to better monetize their data, create richer engagements with their customers, and make better investments as they grow their businesses. The Kepler platform is designed to enable businesses of all sizes to create, test, deploy and scale their AI projects with smaller teams and a minimal learning curve, making it a great fit for leAD’s diverse roster of innovative startups.”

Stradigi AI has become one of leAD’s official technology partners with an exclusive offer for leAD’s program in Lake Nona, a smart city designed to accelerate innovation and well-being in Orlando, FL. To be eligible to benefit from this partnership offer, startups have to be accepted in the leAD Lake Nona Sports & Health Tech program. The program, which kicks off in 2020 with a virtual phase, provides startups with crucial knowledge to grow their business, extensive guidance, and mentorship, cash investment as well as access to Lake Nona’s world-class facilities and innovation ecosystem. For more information, visit leAD Lake Nona or apply directly on F6S until September 4th, 2020.

More Information About the Kepler Platform

The Kepler platform combines advanced machine learning (ML) — including Deep Learning — with intuitive design, all within a self-serve framework built to help scale AI. Users can tackle high-impact use cases across multiple industries and lines of business with no ML experience required.

About leAD

leAD Sports & Health Tech Partners sources, funds, and drives growth of early-stage sports & health tech startups globally. leAD was founded in 2016 and was inspired by the legend of the sports industry Adi Dassler. Since inception, leAD has taken on new companies into its business every year. With 30 companies from around the globe under its portfolio, leAD is constantly empowering founders to create their own legacy. leAD works with groundbreaking solutions across the verticals of fan engagement, connected athletes, and health & well-being and focuses on driving growth through smart investment, premier network access, and expert training. leAD has three three investment vehicles – Academy, Portfolio, and ADvantage Fund – and commercial partnerships with Citi Private Bank, Tavistock Group, OurCrowd, and Lake Nona to further support portfolio growth.

For more information, visit http://www.leadsports.com.

About Stradigi AI

Stradigi AI is an Artificial Intelligence software company that enables organizations to bring business-accelerating AI to fruition, quickly. Its Machine Learning (ML) platform, Kepler, alleviates the AI talent gap by empowering any type of user with access to intuitive Automated Data Science Workflows, built to generate results for pertinent use cases across the business stack, with no ML experience required. The Kepler platform allows users to extract key insights from their data to improve customer experience, grow revenue, and gain efficiencies across multiple industries including CPG, retail, manufacturing, financial services, logistics, and more.

For more information, visit http://www.stradigi.ai.

Share article on social media or email: